Cesca Therapeutics’ Management Delivers Keynote Speech at the 2017 Shenzhen International Precision Medicine Summit
April 07 2017 - 3:39PM
Cesca Therapeutics Inc. (Nasdaq:KOOL), a market leader in automated
cell processing and point-of-care, autologous cell-based therapies,
today announced that Dr. Xiaochun (Chris) Xu, Chairman and Interim
Chief Executive Officer, delivered the keynote speech, entitled,
“Cell Therapy – The Next Wave of Future Medicine,” at the 2017
Shenzhen International Precision Medicine Summit, which took place
yesterday and today (April 6-7) in Shenzhen, China. The summit was
organized in honor of James D. Watson, Ph.D., who discovered the
double helix structure of DNA in 1953 and later made a significant
contribution to the Human Genome Project.
“As a leading developer of integrated cellular
therapies and delivery systems, Cesca Therapeutics is uniquely
positioned to advance the practice of regenerative medicine
globally and we are therefore honored to have been asked to give
the keynote speech at this important event,” commented Dr. Xu.
“Earlier this year, we announced our intention to further expand
into the China market, which has the world’s largest population and
ranks among its fastest-growing economies. With this in mind, our
long-term goal is to establish a leadership position in China
through an expanded sales network and the creation of scientific
and strategic collaborations that leverage our strong internal
development capabilities in autologous cell-based
therapies.” About the
International Precision Medicine Summit
The 2017 Shenzhen International Precision
Medicine Summit is focused on new advances in precision medicine
and brought together leaders in scientific research, the investment
community and government officials, along with over 1,000 attendees
from different countries. The conference covered hot topics in the
field of immuno-oncology, cancer vaccines, cell therapeutics,
genetic analysis and gene therapies.
About Cesca Therapeutics Inc.
Cesca is engaged in the research, development,
and commercialization of cellular therapies and delivery systems
for use in regenerative medicine. The Company is a leader in the
development and manufacture of automated blood and bone marrow
processing systems that enable the separation, processing and
preservation of cell and tissue therapeutics. Cesca is an affiliate
of the Boyalife Group (http://www.boyalifegroup.com), a China-based
industrial-research alliance among top research institutes for stem
cell and regenerative medicine.
Forward-Looking Statement
The statements contained herein may include
statements of future expectations and other forward-looking
statements that are based on management’s current views and
assumptions and involve known and unknown risks and uncertainties
that could cause actual results, performance or events to differ
materially from those expressed or implied in such statements. A
more complete description of risks that could cause actual events
to differ from the outcomes predicted by Cesca Therapeutics'
forward-looking statements is set forth under the caption "Risk
Factors" in Cesca Therapeutics' annual report on Form 10-K and
other reports it files with the Securities and Exchange Commission
from time to time, and you should consider each of those factors
when evaluating the forward-looking statements.
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2023 to Apr 2024